BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Shingrix: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Aribio Lab Co., Ltd., Shanghai Institute Of Biological Products, Curevo Inc. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P2 | Aribio Lab Co., Ltd. | NCT07481604 Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above | Herpes Zoster | active not recruiting | 135 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-06-30 est. | P1/P2 | Shanghai Institute Of Biological Products | NCT06932523 A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals | Herpes Zoster (HZ) | recruiting | 645 |
| 2026-06-30 est. | P2 | Curevo Inc | NCT05304351 Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older | Herpes Zoster; Shingles | active not recruiting | 1516 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.